Drug Trial Radar · NCT00433459
Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma
Last checked: Nov 20, 2026Latest source record: Mar 26, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,134
Actual
Start
Jan 2007
Primary completion
Jan 2013
Study completion Jan 2013
Sponsor
- Lead sponsor
- Christine Mauz-KörholzAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Deutsche Krebshilfe e.V., Bonn (Germany); Euronet Worldwide
- First posted
- Feb 12, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens to compare how well they work in treating young patients with Hodgkin's lymphoma.
Conditions
- Lymphoma
Interventions
cyclophosphamideDrug
drug is used in first line treatment in combination (COPP or COPDAC)
dacarbazineDrug
drug is used in first line treatment in combination (COPDAC)
prednisoloneDrug
drug is used in first line treatment in combination (OEPA, COPP or COPDAC)
prednisoneDrug
drug is used in first line treatment in combination (OEPA, COPP or COPDAC)
procarbazine hydrochlorideDrug
drug is used in first line treatment in combination (COPP)
vincristine sulfateDrug
drug is used in first line treatment in combination (OEPA, COPP or COPDAC)
fludeoxyglucose F 18Radiation
used as a diagnostic marker for metabolically active tumour at staging and response assessment
radiation therapyRadiation
part of combination treatment (combined modality between chemo- and radiotherapy)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free survivalTime frame: 5 years
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Universitaetsklinikum Giessen-Marburg
Giessen, Germany
Royal Hospital for Sick Children
Edinburgh, Scotland, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.